Pre-made Pagibaximab benchmark antibody (Whole mAb, anti-Staphylococcus epidermidis lipoteichoic acid therapeutic antibody) for drug discovery and mechanism of action (MOA) research

Cat No.: GMP-Bios-INN-944

Anti-Staphylococcus epidermidis lipoteichoic acid therapeutic antibody (Pre-made Pagibaximab biosimilar, Whole mAb) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.

Pagibaximab is a chimeric monoclonal antibody for the prevention of staphylococcal sepsis in infants with low birth weight. As of March 21[update], it is undergoing Phase II/III clinical trials.[1][2]

Order information


* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry

Catalog No. Package Price(In USD) Qty (Quantity) Sum(In USD)
GMP-Bios-INN-944-1mg 1mg 3090
GMP-Bios-INN-944-10mg 10mg Inquiry
GMP-Bios-INN-944-100mg 100mg Inquiry
GMP-Bios-INN-944-xmg ≥100mg Inquiry
Shipping Cost: 760.00
Total:

For more than 100mg, click here for inquiry. >>


Description

Products Name (INN Index) Pre-Made Pagibaximab Biosimilar, Whole Mab: Anti-Staphylococcus Epidermidis Lipoteichoic Acid therapeutic antibody
INN Name Pagibaximab
TargetStaphylococcus epidermidis lipoteichoic acid
FormatWhole mAb
DerivationChimeric
Species Reactivityhuman
CH1 IsotypeIgG1 - kappa
VD LCIgG1 - kappa
Highest_Clin_Trial (Jan '20)
Est. Status
100% SI Structure
99% SI Structure
95-98% SI Structure
Year Proposed
Year Recommended
CompaniesMedImmune (Gaithersburg MD USA) / AstraZeneca (London UK)
Conditions Approved
Conditions Active
Conditions Discontinued
Development Tech0